Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

NEW DRUGS

Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression

JHOP - April 2021 Vol 11, No 2 - FDA Oncology Update, Myelosuppression
Download PDF

On February 12, 2021, the FDA approved trilaciclib (Cosela; G1 Therapeutics), as a first-in-class cyclin-dependent kinase (CDK)4/6 inhibitor to reduce the frequency of chemotherapy-induced myelosuppression in adults with extensive-stage small-cell lung cancer, when used before a platinum plus etoposide regimen or a topotecan-containing regimen. Trilaciclib may prevent damage to bone marrow cells by inhibiting the CDK4/6 enzyme. The FDA granted trilaciclib priority review and a breakthrough therapy designation.

“For patients with extensive-stage small-cell lung cancer, protecting bone marrow function may help make their chemotherapy safer and allow them to complete their course of treatment on time and according to plan,” said Albert Deisseroth, MD, PhD, Supervisory Medical Officer at the FDA’s Center for Drug Evaluation and Research. “Today’s approval of Cosela will give patients a treatment option that can reduce the occurrence of a common, harmful side effect of chemotherapy.”

The FDA approved trilaciclib based on data from 3 randomized, double-blind, placebo-controlled studies with a total of 245 patients who were randomized to intravenous trilaciclib or to placebo before chemotherapy. The study compared the incidence rate and duration of severe neutropenia in the first cycle of chemotherapy.

In all 3 studies, patients who received trilaciclib had a lower risk for severe neutropenia than those who received placebo, as well as a shorter duration of severe neutropenia.

The most common (≥10%) adverse events were fatigue, increased levels of aspartate aminotransferase, headache, pneumonia, and deficiencies in calcium, potassium, and phosphate. The grade 3 or 4 hematologic adverse reactions to trilaciclib included neutropenia (32%), thrombocytopenia (18%), anemia (16%), leukopenia (4%), and febrile neutropenia (3%). Trilaciclib therapy is associated with the risk for acute drug hypersensitivity, interstitial lung disease, and pneumonitis.

Related Items
Gavreto Received Regular FDA Approval for Patients With Non–Small Cell Lung Cancer and RET Gene Fusion
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Akeega, First and Only Dual-Action Tablet for Metastatic Prostate Cancer With BRCA Mutation
Online First published on September 8, 2023 in FDA Oncology Update
FDA Granted Accelerated Approval to Elrexfio, a Bispecific BCMA-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Online First published on September 8, 2023 in FDA Oncology Update
Hepzato Kit FDA Approved as a Liver-Directed Treatment for Uveal Melanoma With Hepatic Metastases
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Columvi for Selected Relapsed or Refractory Large B-Cell Lymphomas
JHOP - August 2023 Vol 13, No 4 published on August 17, 2023 in FDA Oncology Update
Lonsurf Received a New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer
JHOP - August 2023 Vol 13, No 4 published on August 7, 2023 in FDA Oncology Update
Jemperli Plus Chemotherapy Now FDA Approved for Front-Line Treatment of dMMR or MSI-H Endometrial Cancer
JHOP - August 2023 Vol 13, No 4 published on August 4, 2023 in FDA Oncology Update
Vanflyta Now Approved for Newly Diagnosed FLT3-ITD–Positive AML
JHOP - August 2023 Vol 13, No 4 published on July 28, 2023 in FDA Oncology Update
Talzenna Received a New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation
JHOP - August 2023 Vol 13, No 4 published on June 30, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.